General
Preferred name
POSACONAZOLE
Synonyms
Posaconazole (hydrate) ()
SCH 56592-D5 ()
SCH56592 hydrate ()
SCH 56592 ()
POS ()
SCH 56592,POS,Noxafil ()
Posaconazole hydrate ()
Posaconazole (SCH 56592) ()
Posaconazole-d5 ()
Noxafil powdermix kit ()
Posaconazole sp ()
(-)-posaconazole ()
SCH-56592 ()
Posaconazol ()
Posaconazole ahcl ()
Noxafil ()
Posaconazole accord ()
P&D ID
PD011039
CAS
171228-49-2
1198769-38-8
2649530-57-2
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
2006
2005
Drug indication
Aspergillosis
Drug Status
vet_approved
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Posaconazole is a broad-spectrum, second generation, antifungal drug. It inhibits the fungal lanosterol 14α-demethylase, which reduces production of ergosterol (an important component of the fungal cell wall).
(GtoPdb)
DESCRIPTION
Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity.
PRICE
119
DESCRIPTION
Posaconazole (POS) is a sterol C14?? demethylase inhibitor (IC50: 0.25 nM).
DESCRIPTION
Posaconazole (POS) is a sterol C14ɑ demethylase inhibitor (IC50: 0.25 nM).
(TargetMol Bioactive Compound Library)
DESCRIPTION
Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Posaconazole is a sterol C14ɑ demethylase inhibitor with an IC50 of 0.25 nM. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase. Posaconazole is the most advanced candidate for the treatment of Chagas disease. Posaconazole has entered in a phase II clinical trial in the treatment of mycoses.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
5
Compound Sets
26
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Pathogen Box
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
73
Molecular Weight
700.33
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
1
Rotatable Bonds
12
Ring Count
7
Aromatic Ring Count
5
cLogP
4.57
TPSA
115.7
Fraction CSP3
0.41
Chiral centers
4.0
Largest ring
6.0
QED
0.2
QED
0.2
Structural alerts
1
anil_di_alk_C(246)
c:1:c:c(:c:c:c:1-[#8]-[#6;X4])-[#7;$([#7!H0]-[#6;X4]),$([#7](-[#6;X4])-[#6;X4])]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target
Fungal
CYP3A4
Antifungal agent
Parasite
P450 (e.g. CYP17)
Disease
REFERENCE COMPOUNDS
Pathway
Anti-infection
Microbiology/virology
MOA
Antifungal
sterol demethylase inhibitor
Indication
oropharyngeal candidiasis
ATC
J02AC04
Therapeutic Class
Antifungal Agents
Source data
